Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

SPLUNC1 may be marker of flares, treatment response in children

A protein secreted into the airways, called SPLUNC1, may be a sensitive biomarker of both mild pulmonary exacerbations and treatment response in children with cystic fibrosis (CF), a study suggested. Data showed that SPLUNC1 levels in patients’ sputum were low during an exacerbation, then significantly rose after oral and,…

Zinc may help fight bacterial infections in CF patients: Study

Zinc may be key to reducing bacterial infections in people with cystic fibrosis (CF), researchers at the University of Queensland have found. They discovered that defects in the CFTR protein, the underlying cause of CF, interfered with the bacteria-killing function of immune cells known as macrophages. They were able…

Phase 1 trial of SION-109 oral therapy doses first volunteer

The first volunteer has been dosed in a Phase 1 clinical trial evaluating SION-109, an experimental oral treatment for cystic fibrosis (CF), as announced by Sionna Therapeutics, the therapy’s developer. After receiving the green light from the U.S. Food and Drug Administration, the trial has enrolled healthy volunteers to…

US study examines lung function decline in younger CF patients

Various social and environmental factors in different locations across the U.S. influenced a decline in lung function among adolescents and young adults with cystic fibrosis (CF), a large-scale analysis demonstrated. CF patients with early lung function decline tended to live in areas with more social-environmental adversity, such as higher…